A
Artiva Biotherapeutics
NK cell therapy for cancer patients
About Artiva Biotherapeutics
Artiva Biotherapeutics is a biotech startup that operates in the field of immunotherapy, specifically focusing on the development of cell therapies for cancer and autoimmune diseases. The company's primary mission is to create effective, safe, and accessible treatments for patients suffering from these devastating conditions.
Read full description
Artiva's business model revolves around the production of off-the-shelf, allogeneic NK cell therapies. Allogeneic means the cells are harvested from a donor, not the patient, which allows for mass production and reduces the time and cost associated with patient-specific manufacturing. This approach aims to make cell therapy more accessible to a larger number of patients.
The company's flagship product is AlloNK®, a non-genetically modified NK cell therapy. It is designed to enhance the activity of monoclonal antibodies or NK cell engagers, which are proteins designed to bind to specific targets on cancer cells. AlloNK® is currently undergoing clinical trials for the treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and Non-Hodgkin Lymphoma. It is also being tested in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.
Artiva generates revenue through the development, clinical testing, and eventual commercialization of its cell therapies. The company's target market includes patients with autoimmune diseases and various forms of cancer, as well as healthcare providers and institutions that treat these conditions.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- San Diego, United States
- Listing
- IPO 2024
- Employees
- 111
- Open positions
- 24
- Dealroom signal
- 78.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Artiva Biotherapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | May 2026 | $300M | — | Adage Capital · RA Capital Management · EcoR1 Capital · Samsara BioCapital | ↗ |
| IPOOther financing | Jul 2024 | $167M | $167M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $0 | — | −$87M | — |
| 2025 | $0 | -100% | −$87M | — |
| 2024 | $251K | -99.3% | −$68M | -27270.1% |
| 2023 | $33M | +579.2% | −$29M | -86.9% |
| 2022 | $4.9M | +146.3% | −$59M | -1189.8% |
| 2021 | $2M | — | −$72M | -3575.3% |
| 2020 | $0 | — | −$18M | — |
Growth signals
Latest recorded traffic for Artiva Biotherapeutics is 7K monthly website visits, up 100% over the last three months. Artiva Biotherapeutics's team grew 7.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- GPGC Pharma
GC LabCell
Series A16 investors entered at this stage
5AM Ventures
venBio Partners
RA Capital Management
Green Cross- MPMedivate Partners
- VPVenrock Healthcare Capital Partners
Wellington Management
Citadel
Cormorant Asset Management
EcoR1 Capital
Logos Capital
Venrock
Franklin Templeton Investments
RTW Investments
Janus Henderson Investors- APAcuta Capital Partners
Series B and later7 investors entered at this stage
Adage Capital
Samsara BioCapital
GC Cell
Blackstone
Viking Global Investors
Caligan Partners
Blue Owl Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Artiva Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Artiva Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.